The aberrant activation of HGF/MET signaling pathway arises from overexpression, MET gene amplification or activating mutations, as well as excessive autocrine or paracrine HGF secretion, which has been reported to be associated with the development and progression of many types of cancers including lung, renal, gastrointestinal, thyroid, and breast cancers as well as glioblastoma among others (Zhang et al., 2018; Fu et al., 2021). The gene discussed is MET; the disease is breast carcinoma.